Table 4.

Effect of FSK, Glibenclamide and Atorvastatin on TBARS, glutathione, SOD and catalase

Groups	TBARS (nmol/mg)	GSH (μM/mg protein)	SOD (µmol/min/mL)	Catalase (nmol H2O2 consumed/min/mL)
Normal Control	0.60 ± 0.09	232.6 ± 11.83	14.22 ± 0.85	7.61 ± 0.57
FSK per se	0.62 ± 0.06	232.9 ± 10.75	13.29 ± 1.11	7.17 ± 0.51
Diabetic Control	1.77 ± 0.12a	97.71 ± 10.95a	3.64 ± 0.94a	2.51 ± 0.44a
FSK-10 in Diabetic group	1.66 ± 0.09a	106.6 ± 10.39a	4.62 ± 0.63a	3.02 ± 0.29a
FSK-20 in Diabetic group	1.47 ± 0.08b	136.4 ± 9.88b	9.14 ± 0.69b	4.37 ± 0.39b
FSK-30 in Diabetic group	1.17 ± 0.07b,c	162.90 ± 12.54b,c	10.71 ± 0.78b,c	5.24 ± 0.33b,c
Glibenclamide in Diabetic group	0.99 ± 0.09b,d	197.0 ± 12.94b,d	12.25 ± 0.94b,d	6.14 ± 0.36b,d
Atorvastatin in Diabetic group	1.57 ± 0.08b	139.3 ± 13.05b	9.00 ± 0.81b	4.31 ± 0.56b
Glibenclamide + FSK-30 in Diabetic group	0.75 ± 0.09b,e	230.6 ± 16.25b,e	13.79 ± 0.69b,e	6.98 ± 0.40b,e
Atorvastatin + FSK-30 in Diabetic group	1.02 ± 0.10b,f	175.90 ± 10.88b,f	12.00 ± 1.00b,f	5.58 ± 0.29b,f

Values are expressed as Mean ± SD (n = 7 per group).

^aP < 0.05 vs normal control, FSK per se group;

^bP < 0.05 vs diabetic control & FSK-10 mg/kg treated group;

^cP < 0.05 vs FSK-20 mg/kg treated group;

^dP < 0.05 vs FSK-30 mg/kg treated group;

^eP < 0.05 vs GB-0.6 mg/kg treated group;

^fP < 0.05 vs Atorvastatin-0.5 mg/kg treated group.